A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this investigator-initiated, a single-arm, open-label, pilot study is to
investigate the safety, tolerability, and efficacy of CD-801 treatment in subjects with
advanced hepatocellular carcinoma.
Condition of disease: advanced hepatocellular carcinoma .
Intervention：treatment with 100μg CD-801 through the hepatic artery at two-week intervals.
The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For
example, it may be adjusted to administer the medication once every three weeks or four
weeks.
Drug: CD-801, a drug designed specifically to enhance the expression of HNF4α and selectively
target liver cancer cells.